A technique of midazolamljentanyllisofluranelnitrous oxide anaesthesia, in which the benzodiazepine was antagonised by the specific antagonist, flumazenil, was compared with propofollfentanyllnitrous oxide anaesthesia for minor outpatient urological surgery. No significant difference was found in the overall ease of anaesthesia; however, using subjective (linear analogue sedation scales) and objective (letter deletion and simple reflex time) tests, recovery was found to be significantly slower for the antagonised midazolam group. For both groups, the most frequent intraoperative problem was patient movement in response to surgical stimulation and, postoperatively, headache. The midazolam group displayed the greatest degree of residual sedation at the 4-hour time of discharge and on arrival home a significantly larger number of patients in the midazolam group slept for a period. It is likely that the dose offlumazenil chosen ( 1 mg) was inadequate to completely antagonise the dose of midazolam (mean 17 mg) for the full duration of recovery.
Flumazenil is an imidazo benzodiazepine shown to be a partial agonist at the benzodiazepine receptor and capable of antagonising benzodiazepine agonist action. 6 ,7 It represents the first clinically reliable method of reversing the sedative and hypnotic effects of the benzodiazepines and its ability to do this suggests the technique of antagonised benzodiazepine anaesthesia for outpatients.
The purpose of this study was to compare the recovery aspects of midazolam/nitrous oxide/isoflurane anaesthesia with those of propofol/nitrous oxide when flumazenil is used to reverse the residual effects of the benzodiazepine. Isoflurane was added to the midazolam regimen when difficulty was found in an initial pilot study maintaining satisfactory anaesthesia with midazolam/nitrous oxide alone. METHODS Informed consent was obtained from forty un premedicated patients aged 20-60 years undergoing day-case cystoscopy. The subjects were ASA 1-2 and were taking no regular psychotropic medications. They were randomly allocated to one of two groups each comprising fourteen men and six women.
Both groups received fentanyl 1.0 ~g/kg one minute prior to induction through a 21 gauge needle in the right antecubital fossa. Anaesthesia in both groups was supplemented with 70% nitrous oxide via a circle absorption system.
Group 1 patients received propofol 1.0 mg/kg as a rapid five-second bolus, followed by 10 mg increments at fifteen-second intervals until loss oflash reflex. Supplements of 10 mg of propofol were given as required to maintain anaesthesia. Group 2 patients received midazolam 10 mg with 5 mg increments every two minutes until loss of lash reflex and isoflurane was given in 0.5% increments at the lowest possible level to maintain satisfactory anaesthesia.
Prior to induction a subjective and objective psychomotor/sedation test battery (see below) was performed and repeated at 30, 120 and 240 minutes postoperatively. In addition, simple line diagrams were shown to patients at these times for subsequent recall at 24 hours.
In recovery a second anaesthetist, blind to the anaesthetic technique, administered in a double-blind manner normal saline 10 ml mtravenously to group 1 patients and flumazenil 10 ml (1 mg) to group 2 patients.
Time to open eyes on command was noted and sedation assessed, using a five point scoring system (Table 1) , prior to the injection Wide awake, alert of flumazenil placebo and at 2, 5, 10, 20 and 30 minutes. Patient anxiety was also rated at these times as were heart rate, blood pressure and respiratory rate.
All patients remained in the recovery room for four hours postoperatively at which time they completed a short questionnaire to assess their degree of subjective recovery before being discharged.
The subjects were asked to complete a questionnaire on the day following surgery regarding the degree of sedation, presence of side effects and recall of the line diagrams.
Subjective and objective tests of recovery were analysed using an analysis of variance and covariance and Mann-Whitney U tests. Between-groups parametric data was analysed by Students t-tests and side effects by a chisquared test.
Psychomotor/sedation test battery
Visual analogue sedation scale. Patients were asked to assess their degree of sedation by marking a 10 cm linear analogue scale. The extremes were denoted wide awake/alert and drowsy/dull.
Letter deletion test. Thirty lines of 25 randomly typed upper and lower case letters were given and subjects deleted as many letters g or G in a two-minute time interval as possible.
Reflex time. Simple reflex time was assessed on an Apple lIe microcomputer as the time taken to press a button after a visual light stimulus. The mean reflex time was taken as the average for the last 30 of 35 attempts.
RESULTS
There was no significant difference in age, weight, or length of operation between the two groups ( Table 2) .
The mean induction dose of propofol was 137 (SD 46) mg (1.7 mg/kg), with a mean dose of 62 mg (0.85 mg/kg) required for maintenance. The mean induction dose ofmidazolam was 17 (SD 6) mg (0.23 mg/kg), the required dose not correlating with age, sex or weight. Only one patient did not require isoflurane for maintenance of anaesthesia, the median concentration required was 1.5% (range 0 .. :3%). The most frequent complication noted during anaesthesia (Table 3 ) was patient movement related to surgical stimulation (20% incidence in both groups), otherwise the anaesthetic was recorded as easy and completely successful by the anaesthetist in 70% of the midazolam group and 80% of the propofol group (Table 4 ).
The number of patients remaining asleep after injection of flumazenil/placebo is shown in Figure 1 Injection compared with one in the midazolam group. Following the injection of flumazenil all but one midazolam patient awoke within three minutes (mean time to open eyes, 90 (SD 120) seconds). The mean value for the observer's assessment of sedation score for the first 30 minutes after anaesthesia is shown in Figure   2 . Significantly greater sedation (P < 0.01) was found for the midazolam group immediately prior to flumazenil injection and at one minute but was not significant for the remainder of the initial 30-minute period.
Mean change in reflex time and letter deletion test scores for the subsequent fourhour recovery period are shown in requirement for midazolam or propofol correlated with the degree of psychomotor impairment. Change in self-rated sedation visual analogue scale results are shown in Figure 5 . The midazolam group felt significantly more sedated throughout the recovery period. No significant difference was noted between groups either in the anaesthetist's assessment of patient anxiety immediately following antagonist/placebo or in the subsequent selfrated anxiety (visual analogue scale) data. Line diagram recall at 24 hours did not differ significantly between the two groups.
Heart rate (76 vs 59, P<O.Ol) and respiratory rate (17 vs 13, P < 0.05) were higher in the midazolam group on arrival in recovery, otherwise there were no other significant between-groups differences in physiological variables at any of the time intervals monitored. After the injection of flumazenil systolic pressure rose (15%), diastolic pressure rose (18%), heart rate fell (-6%) and respiratory rate fell (-12%). The mean values are shown in Figures 6 and 7 . In both groups the incidence of side effects during recovery was low and not significantly different between the two groups ( Table 5 ). Prior to discharge at four hours, fewer of the midazolam group felt fully awake or able to perform their normal daily activities ( Table 6) .
Eighty-five per cent of the 24-hour questionnaires were returned (n = 17 each group). Six of the midazolam group and two of the propofol group went to bed on their arrival home and a significantly greater number of midazolam patients slept for a period; otherwise there were no differences in post discharge recovery ( Table 7) .
The overall rating of the day-case experience by the subjects was good or very good in 80% of both groups .
DISCUSSION
Midazolam is limited as an induction agent for outpatient anaesthesia primarily because of its delayed recovery. In addition, common to all benzodiazepines are the problems of variable efficacy and the limited degree of central nervous system depression they can produce (the ceiling effect). With the introduction of flumazenil, the problem of delayed recovery might be overcome and its use would allow the employment of higher benzodiazepine doses to obviate some of the problem of variable efficacy.
In this study we compared the anaesthetic recovery characteristics of propofol with those of antagonised benzodiazepine/isoflurane anaesthesia.
Both techniques were rated highly by the anaesthetist and the incidence of intraoperative complications was low. Both groups rapidly returned to consciousnes with few immediate side-effects noted. Delayed recovery (nine minutes to open eyes on command) occurred in one patient receiving the antagonist, but this was not associated either with a high dose of midazolam (10 mg) or isoflurane (1.5%). The incidence of side-effects in recovery was low for both groups with only one patient in each having nausea and none vomiting, a lower incidence than that found for a technique of outpatient anaesthesia in which we used methohexitone. 8 The most frequent side-effect in this study was headache occurring in 20%-25% of cases, values similar to that found previously for the methohexitone study. 8 At all time intervals up to four hours the propofol group made a significantly better recovery in terms of both objective psychomotor testing and subjective self assessment. At four hours, significantly more patients in the midazolam group felt sedated and four patients experienced some difficulty getting. home because of sedation or unsteadiness.
It is possible that these differences in recovery may have been due to the use of isoflurane in the midazolam group, although this would seem unlikely as recovery from that agent is generally rapid. 9 Another explanation may relate to the partial agonist properties of flumazenil, as it may not be capable of completely reversing benzodiazepine agonist sedation. Preclinical studies suggest however that the agonist activity is weak 10 and therefore should not significantly contribute to post reversal sedation.
A more probable explanation is that the 1.0 mg dose of flumazenil was insufficient to completely reverse the dose of midazolam for the whole four-hour period. A previous study found that a median dose of only 0.4 mg was required to reverse a mean total midazolam dose of 36 mg. 6 However, those authors used the Steward coma scale to assess recovery rather than objective psychomotor tests.
Because the elimination half-life of flumazenil is less than that of midazolam (0.9, SD 0.211 vs 1.8, SD 0.8 hours?) rebound sedation may theoretically occur and although no overt evidence was seen for this in our study, the competitive balance between falling midazolam (and volatile anaesthetic) and antagonist plasma levels could have occurred in such a way as to provide residual benzodiazepine effect without a secondary deterioration in performance. An additional dose of flumazenil administered during the recovery period may have resolved this problem. Anxiety following initial administration of higher doses of flumazenil has been recorded;12,13 however, we found no significant between-group differences in post reversal anxiety suggesting either that the dose and method of administration of flumazenil were appropriate for avoiding this adverse effect or the effect was blocked by the residual effects of the other agents administered.
The apparent lack of significant amnesia during the immediate postoperative period in both groups suggests that flumazenil reverses 4 3 ns The development of flumazenil and propofol are important pharmacological advances and both are certain to have a useful role in day-case anaesthesia. In this study we found that recovery from propofol anaesthesia was significantly better than from antagonised benzodiazepine/isoflurane anaesthesia: both techniques, however, were equally acceptable to patient and anaesthetist and were associated with a low incidence of side-effects. The observed difference in recovery may have been due to an insufficient dose of antagonist and warrants further study.
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